William J. Bussiere, Jr.
- Cheetah Medical, a provider of noninvasive hemodynamic monitoring devices, in connection with its sale to Baxter International Inc. (NYSE:BAX)
- Aura Biosciences in its $30M and $40M financings to advance the clinical development of its Ocular Melanoma treatment
- Synlogic (NASDAQ:SYBX) in its IPO by way of a reverse merger with Mirna Therapeutics, Inc. and its $42M, $40M, $30M and $42M financings to develop “living therapeutics”
- Endotronix in its $37M Series C and $40M Series D financings to develop a medical device system targeting heart failure management
- NBD Nanotechnologies in Series A and Series B financings to develop repellent nanocoatings for consumer products
- John Hancock Financial Network in its sale of Signator Investors to Advisor Group
- Naurex in its sale to Allergan for upfront payment of $560M and additional milestones to commercialize an antidepressant therapy
- Pedro Martinez Foundation in its U.S. relaunch and public charity conversion
Case Study
Mintz represented Granahan Investment Management, a small cap equity investment boutique with $5.8 billion in assets under management, in the recently completed sale of a minority interest in GIM to Kudu Investment Management. GIM’s employees will continue to hold 75% of the equity in the firm.
Case Study
Mintz is advising Vicarious Surgical Inc., a robotics company developing technology that combines human-like surgical robots and virtual reality to perform minimally invasive surgery, in a pending merger with special purpose acquisition company D8 Holdings Corp. that is expected to deliver up to $460 million in gross proceeds.